Sanofi Beats Analyst Estimates on EPS
Sanofi (NYS: SAN) reported earnings on Feb. 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Sanofi missed slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded, and GAAP earnings per share grew significantly.
Gross margins dropped, operating margins improved, and net margins expanded.
Sanofi booked revenue of $11.05 billion. The nine analysts polled by S&P Capital IQ anticipated sales of $11.23 billion on the same basis. GAAP reported sales were 11% higher than the prior-year quarter's $10.47 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $2.03. The seven earnings estimates compiled by S&P Capital IQ predicted $2.02 per share on the same basis. GAAP EPS of $1.41 for Q4 were 213% higher than the prior-year quarter's $0.45 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 68.7%, 200 basis points worse than the prior-year quarter. Operating margin was 19.6%, 120 basis points better than the prior-year quarter. Net margin was 16.1%, 1,050 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $11.48 billion. On the bottom line, the average EPS estimate is $2.28.
Next year's average estimate for revenue is $46.34 billion. The average EPS estimate is $8.01.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sanofi is outperform, with an average price target of $77.37.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Sanofi the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Sanofi to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.